A recent secondary analysis of the WHI further showed that hormone therapy did not increase cardiovascular disease risk in women aged 50–59 years with vasomotor symptoms but was associated with a higher risk in those aged ≥70 years [31], reinforcing the need for safer, age-appropriate alternatives such as ERβ-selective compounds. Here, ESR2 is linked to cardiovascular disorder.